Valeant Pharmaceuticals International Company Profile (NYSE:VRX)

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: VRX
  • CUSIP:
Key Metrics:
  • Previous Close: $30.25
  • 50 Day Moving Average: $25.47
  • 200 Day Moving Average: $34.18
  • 52-Week Range: $18.55 - $245.82
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 3.77
  • P/E Growth: 0.42
  • Market Cap: $10.51B
  • Outstanding Shares: 347,535,000
  • Beta: 0.28
Additional Links:
Companies Related to Valeant Pharmaceuticals International:

Analyst Ratings

Consensus Ratings for Valeant Pharmaceuticals International (NYSE:VRX) (?)
Ratings Breakdown: 4 Sell Ratings, 13 Hold Ratings, 11 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $56.27 (93.84% upside)

Analysts' Ratings History for Valeant Pharmaceuticals International (NYSE:VRX)
DateFirmActionRatingPrice TargetDetails
8/29/2016RBC Capital MarketsReiterated RatingSector Perform$36.00View Rating Details
8/26/2016Morgan StanleyReiterated RatingOverweight$42.00View Rating Details
8/22/2016Deutsche Bank AGReiterated RatingPositiveView Rating Details
8/19/2016Piper Jaffray Cos.Set Price TargetSell$22.00View Rating Details
8/19/2016Canaccord GenuityReiterated RatingHold$31.00 -> $33.00View Rating Details
8/18/2016MizuhoReiterated RatingUnderperform$11.00View Rating Details
8/16/2016Wells Fargo & Co.Reiterated RatingUnderperform$19.50View Rating Details
8/13/2016TD SecuritiesReiterated RatingBuy$38.00View Rating Details
8/11/2016GuggenheimReiterated RatingBuy$55.00View Rating Details
8/10/2016BTIG ResearchReiterated RatingNeutralView Rating Details
8/10/2016Jefferies GroupReiterated RatingBuy$40.00View Rating Details
8/10/2016Royal Bank Of CanadaBoost Price TargetSector Perform$31.00 -> $36.00View Rating Details
8/9/2016Rodman & RenshawLower Price TargetBuy$90.00 -> $81.00View Rating Details
7/26/2016ScotiabankReiterated RatingSector Perform$35.00 -> $32.00View Rating Details
7/25/2016JPMorgan Chase & Co.Set Price TargetHold$35.00View Rating Details
7/20/2016BMO Capital MarketsReiterated RatingMarket Perform$26.00View Rating Details
7/6/2016Stifel NicolausReiterated RatingBuy$55.00View Rating Details
6/7/2016Barclays PLCReiterated RatingHold$34.00View Rating Details
5/29/2016SusquehannaReiterated RatingHold$105.00View Rating Details
5/29/2016S&P Equity ResearchReiterated RatingBuyView Rating Details
4/1/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
3/22/2016NomuraReiterated RatingNeutral$60.00View Rating Details
3/15/2016CIBCDowngradeSector Perform -> Sector Underperform$90.00 -> $24.00View Rating Details
12/21/2015Bank of America Corp.Reiterated RatingBuyView Rating Details
11/23/2015Maxim GroupReiterated RatingHoldView Rating Details
11/2/2015Goldman Sachs Group Inc.DowngradeBuy -> Neutral$180.00 -> $122.00View Rating Details
10/23/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details
10/19/2015Evercore ISIReiterated RatingBuyView Rating Details
7/20/2015JMP SecuritiesBoost Price TargetMarket Outperform$48.00 -> $50.00View Rating Details
7/10/2015Howard WeilInitiated CoverageOutperform$290.00View Rating Details
4/30/2015Cantor FitzgeraldBoost Price TargetBuy$222.00 -> $271.00View Rating Details
2/25/2015CRT CapitalBoost Price TargetBuy$180.00 -> $220.00View Rating Details
10/20/2014AegisReiterated RatingBuyView Rating Details
10/8/2014ING GroupUpgradeBuyView Rating Details
(Data available from 8/31/2014 forward)


Earnings History for Valeant Pharmaceuticals International (NYSE:VRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$1.48$1.40$2.47 billion$2.42 billionViewN/AView Earnings Details
6/7/2016Q116$1.37$1.27$2.34 billion$2.37 billionViewN/AView Earnings Details
3/15/2016Q415$2.61$2.50$2.75 billion$2.80 billionViewListenView Earnings Details
10/19/2015Q315$2.68$2.74$2.06 billion$2.79 billionViewListenView Earnings Details
7/23/2015Q215$2.46$2.58$2.04 million$2.73 millionViewListenView Earnings Details
4/29/2015Q115$2.34$2.36$1.89 billion$2.20 billionViewN/AView Earnings Details
2/24/2015Q414$2.56$2.58$2.23 billion$2.28 billionViewN/AView Earnings Details
10/20/2014Q314$1.99$2.11$2.06 billion$2.06 billionViewListenView Earnings Details
7/31/2014Q214$1.91$1.91$1.06 billion$1.99 billionViewN/AView Earnings Details
5/8/2014Q114$1.72$1.76$1.04 billion$1.85 billionViewN/AView Earnings Details
2/27/2014Q413$2.06$2.15$986.30 million$2.06 billionViewN/AView Earnings Details
10/31/2013Q313$1.40$1.51$884.14 million$1.54 billionViewN/AView Earnings Details
8/7/2013Q213$1.28$1.34$820.09 million$1.10 billionViewN/AView Earnings Details
5/2/2013Q113$1.25$1.30$1.04 billion$1.07 billionViewN/AView Earnings Details
2/28/2013Q412$1.21$1.34$654.17 million$946.67 millionViewN/AView Earnings Details
11/2/2012Q312$1.13$1.15$875.91 million$884.00 millionViewN/AView Earnings Details
8/2/2012$0.99$1.01ViewN/AView Earnings Details
5/3/2012$0.96$0.99ViewN/AView Earnings Details
11/3/2011$0.57$0.66ViewN/AView Earnings Details
8/4/2011$0.65$0.73ViewN/AView Earnings Details
5/9/2011$0.51$0.56ViewN/AView Earnings Details
2/24/2011$0.45$0.51ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Valeant Pharmaceuticals International (NYSE:VRX)
Current Year EPS Consensus Estimate: $6.54 EPS
Next Year EPS Consensus Estimate: $7.71 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161$1.60$1.60$1.60
Q3 20161$1.83$1.83$1.83
Q4 20161$2.10$2.10$2.10
(Data provided by Zacks Investment Research)


Dividend History for Valeant Pharmaceuticals International (NYSE:VRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Valeant Pharmaceuticals International (NYSE:VRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2016Argeris N KarabelasDirectorBuy4,000$24.65$98,600.00View SEC Filing  
6/10/2016Joseph C PapaCEOBuy202,000$24.48$4,944,960.00View SEC Filing  
10/21/2015Ronald Harold FarmerDirectorBuy1,500$181.60$272,400.00View SEC Filing  
7/31/2015Robert L RosielloCFOBuy7,875$254.28$2,002,455.00View SEC Filing  
6/12/2015Robert L RosielloEVPBuy12,900$232.51$2,999,379.00View SEC Filing  
6/9/2015Ronald Harold FarmerDirectorBuy1,000$260.63$260,630.00View SEC Filing  
6/8/2015Ronald Harold FarmerDirectorBuy500$289.20$144,600.00View SEC Filing  
6/2/2015Pavel MirovskyEVPSell38,000$238.01$9,044,380.00View SEC Filing  
5/26/2015Anne Clem WhitakerDirectorBuy7,500$234.67$1,760,025.00View SEC Filing  
5/4/2015Robert Roswell Chai-OnnEVPSell90,938$222.54$20,237,342.52View SEC Filing  
12/10/2014Jeffrey W UbbenInsiderBuy250,000$140.06$35,015,000.00View SEC Filing  
12/3/2014Katharine Berghuis StevensonDirectorBuy1,500$145.73$218,595.00View SEC Filing  
11/24/2014Jeffrey W UbbenInsiderBuy210,000$142.25$29,872,500.00View SEC Filing  
6/23/2014Robert Roswell Chai-OnnEVPSell10,203$121.70$1,241,705.10View SEC Filing  
5/13/2014Robert Roswell Chai-OnnEVPSell10,000$130.08$1,300,800.00View SEC Filing  
4/1/2014Norma Ann ProvencioDirectorSell5,000$132.18$660,900.00View SEC Filing  
3/21/2014Laizer KornwasserEVPBuy2,481$134.97$334,860.57View SEC Filing  
2/3/2014Norma Ann ProvencioDirectorSell5,000$136.23$681,150.00View SEC Filing  
1/24/2014Laizer KornwasserEVPBuy2,536$132.15$335,132.40View SEC Filing  
1/13/2014Norma Ann ProvencioDirectorSell5,000$133.00$665,000.00View SEC Filing  
12/14/2013J. Michael PearsonCEOBuy184,247$81.41$14,999,548.27View SEC Filing  
11/18/2013Laizer KornwasserEVPBuy3,500$107.38$375,830.00View SEC Filing  
11/6/2013Ronald Harold FarmerDirectorBuy1,500$107.98$161,970.00View SEC Filing  
9/13/2013Laizer KornwasserEVPBuy1,000$99.02$99,020.00View SEC Filing  
9/6/2013Norma Ann ProvencioDirectorSell4,000$100.25$401,000.00View SEC Filing  
9/3/2013Norma Ann ProvencioDirectorSell5,000$99.68$498,400.00View SEC Filing  
8/29/2013Fred HassanDirectorBuy51,000$99.01$5,049,510.00View SEC Filing  
8/28/2013Ronald Harold FarmerDirectorBuy2,500$102.36$255,900.00View SEC Filing  
8/23/2013Robert Roswell Chai-OnnEVPBuy5,032$99.30$499,677.60View SEC Filing  
8/12/2013Brian StolzEVPBuy4,500$100.71$453,195.00View SEC Filing  
8/9/2013Laizer KornwasserEVPBuy3,500$100.36$351,260.00View SEC Filing  
6/19/2013G Mason MorfitInsiderBuy1,352,941$85.00$114,999,985.00View SEC Filing  
6/12/2013Lloyd Mitchell SegalDirectorBuy3,190$84.16$268,470.40View SEC Filing  
6/11/2013Norma Ann ProvencioDirectorSell6,000$85.26$511,560.00View SEC Filing  
3/11/2013Laizer KornwasserEVPBuy2,000$70.61$141,220.00View SEC Filing  
11/7/2012Brian M StolzEVPBuy2,040$52.76$107,630.40View SEC Filing  
11/6/2012Howard Bradley SchillerCFOBuy18,300$54.10$990,030.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Valeant Pharmaceuticals International (NYSE:VRX)
DateHeadline logoValeant Pharmaceuticals International, Inc. (VRX) Sued In New York Over Philidor Ties - TCC (NYSE:VRX) - August 30 at 7:53 PM
News IconWhich way Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earnings may go - The Voice Registrar (NYSE:VRX) - August 30 at 7:53 PM logo5:01 pm Valeant Pharma announces that Chairman and CEO Joseph C. Papa will participate in two healthcare conferences in September (NYSE:VRX) - August 30 at 7:53 PM logoOrexigen Shares Up 14% After Commercialization, Distribution Deal With Valeant Canada - Benzinga (NYSE:VRX) - August 30 at 11:29 AM
News IconToday's Top Gainers in the Market Valeant Pharmaceuticals International, Inc. (NYSE:VRX) from Healthcare - The Daily Leicester (NYSE:VRX) - August 29 at 7:16 AM logoTime to Shift Your Focus (NYSE:VRX) - August 28 at 7:09 AM logoValeant Pharmaceuticals International, Inc. (VRX) Shares Are Rising Following Management Meeting: Here's Why - TCC (NYSE:VRX) - August 27 at 7:13 AM
News IconTop Gainers of the Day: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) from Drug Delivery (NYSE:VRX) - August 26 at 7:45 PM logoValeant Pharmaceuticals International, Inc. (VRX) Shares Are Rising Following Management Meeting: Here's Why (NYSE:VRX) - August 26 at 11:01 AM logo[$$] Hong Kong watchdog finds short seller culpable of market misconduct (NYSE:VRX) - August 26 at 11:01 AM logoValeant Pharmaceuticals Intl Inc (VRX) Reveals Series of Executive Committee Changes - Smarter Analyst (NYSE:VRX) - August 24 at 11:13 AM logoValeant Pharma (VRX) Offers Details on Incoming CFO Herendeen's Compensation; Will Get $10M in 'Make-Up Cash' (NYSE:VRX) - August 23 at 8:17 PM logoValeant Pharmaceuticals Intl Inc Reveals Series of Executive Committee Changes (NYSE:VRX) - August 23 at 8:17 PM logo4 Big-Name Investment Funds That Strongly Believe in a Valeant Pharmaceuticals Turnaround (NYSE:VRX) - August 23 at 8:17 PM logoVALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation (NYSE:VRX) - August 23 at 8:17 PM logoValeant Pays up for New CFO Herendeen (NYSE:VRX) - August 23 at 8:17 PM
News IconActive Stocks' Revenge with Bears- Valeant Pharmaceuticals International (NYSE:VRX), Rovi (NASDAQ:ROVI ... - Seneca Globe (NYSE:VRX) - August 23 at 12:26 PM logoValeant: $55 Price Target Reaffirmed - Seeking Alpha (NYSE:VRX) - August 23 at 12:26 PM
News IconValeant Names Zoetis Executive as Financial Chief--Update (NYSE:VRX) - August 22 at 8:05 PM logoValeant Pharma (VRX) Names Paul Herendeen as CFO (NYSE:VRX) - August 22 at 8:05 PM
News IconEmbattled Valeant Poaches New CFO From Zoetis (NYSE:VRX) - August 22 at 8:05 PM logoValeant Pharma (VRX) Names Paul Herendeen as CFO - (NYSE:VRX) - August 22 at 6:54 AM logoValeant has poached a new CFO from the animal-health company Zoetis (NYSE:VRX) - August 22 at 6:54 AM logoValeant Names Herendeen From Zoetis as CFO to Replace Rosiello (NYSE:VRX) - August 22 at 6:54 AM logoValeant names former Zoetis executive Paul Herendeen as CFO (NYSE:VRX) - August 22 at 6:54 AM logoValeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer (NYSE:VRX) - August 22 at 6:54 AM logoValeant names Paul Herendeen as new CFO (NYSE:VRX) - August 22 at 6:54 AM
News IconWatchful Active Movers- Valeant Pharmaceuticals International ... - Seneca Globe (NYSE:VRX) - August 19 at 7:59 PM logoCanaccord Raises Price Target on Valeant Pharmaceuticals International, Inc. (VRX) on Back of Credit Facility ... - Smarter Analyst (NYSE:VRX) - August 19 at 7:59 PM logoValeant Again Able to Loosen Debt Terms (NYSE:VRX) - August 19 at 11:06 AM logoValeant Stock Down on Lawsuit by T. Rowe, Alters Credit Loan (NYSE:VRX) - August 19 at 11:06 AM logoAllergan (AGN) Stock Should Outperform, Analyst Tells CNBC (NYSE:VRX) - August 19 at 11:06 AM logoValeant Pharmaceuticals International, Inc.'s (NYSE:VRX) Credit Agreement Amendment is Positive, Says Analyst (NYSE:VRX) - August 18 at 8:24 PM logoFraud Accusations Spark Bearish Betting on Valeant Pharmaceuticals Intl Inc (VRX) (NYSE:VRX) - August 18 at 8:24 PM logoWhy Valeant Pharmaceuticals is Tanking (NYSE:VRX) - August 18 at 8:24 PM
News IconUpdate on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for the day (NYSE:VRX) - August 18 at 8:24 PM logoValeant's New Debt Agreement Comes With Freedom to Miss Forecast - Bloomberg (NYSE:VRX) - August 18 at 5:37 PM logoCANADA STOCKS-TSX nearly flat as energy stocks gain offset by telecoms, banks (NYSE:VRX) - August 18 at 11:18 AM logo[$$] T. Rowe Price Sues Valeant, Alleging 'Fraudulent Scheme' (NYSE:VRX) - August 18 at 11:18 AM logoValeant: Morgan Stanley's Target Should Be Closer To $55 (NYSE:VRX) - August 17 at 11:06 AM logoValeant Wins Huge Upgrades, Shares Rebound (NYSE:VRX) - August 17 at 11:06 AM
News IconIf Valeant Pharmaceuticals Intl Inc Does THIS, VRX Stock Could Soar (NYSE:VRX) - August 17 at 11:06 AM logoValeant Wins Upgrade From Morgan Stanley (NYSE:VRX) - August 17 at 11:06 AM logoValeant Pharmaceuticals: The Power of a Morgan Stanley Upgrade (NYSE:VRX) - August 17 at 11:06 AM logoWhy Valeant Got Its First Big Analyst Upgrade of 2016 (NYSE:VRX) - August 17 at 11:06 AM logoMorgan Stanley Says It's Time to Buy Valeant Again (NYSE:VRX) - August 17 at 11:06 AM logoLone Star Raises New Stake in Valeant Pharmaceuticals International, Inc. (NYSE:VRX): 13F - TCC (NYSE:VRX) - August 16 at 8:15 PM logoHey, Valeant Pharmaceuticals, Less Bad Still Isn't Good (NYSE:VRX) - August 16 at 8:15 PM logoFidelity Was a Big Second-Quarter Buyer of Valeant Shares (NYSE:VRX) - August 16 at 8:15 PM logoValeant: It's Neither Easy Nor Simple - Seeking Alpha (NYSE:VRX) - August 15 at 8:33 PM


Valeant Pharmaceuticals International (NYSE:VRX) Chart for Wednesday, August, 31, 2016

Last Updated on 8/31/2016 by Staff